Oric Pharmaceuticals Inc Market Cap ($968.12 Million)
Market Cap & Net Worth: Oric Pharmaceuticals Inc (ORIC)
Oric Pharmaceuticals Inc market cap. Oric Pharmaceuticals Inc (NASDAQ:ORIC) has a market capitalization of $968.12 Million ($968.12 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8752 globally and #2530 in its home market, demonstrating a 3.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oric Pharmaceuticals Inc's stock price $9.34 by its total outstanding shares 103652656 (103.65 Million). Also see Oric Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Oric Pharmaceuticals Inc Market Cap History (2020–2026)
Oric Pharmaceuticals Inc market cap history from 2020 to 2026. Data shows change from $3.51 Billion to $968.12 Million (-14.39% CAGR). Check ORIC stock price and chart for real-time trading data and today's change.
Index Memberships
Oric Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.04% | #252 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #945 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.05% | #144 of 263 |
Weight: Oric Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oric Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oric Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ORIC year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ORIC by Market Capitalization
Companies near Oric Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see ORIC total asset value for a full breakdown of the balance sheet.
Key companies related to Oric Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Oric Pharmaceuticals Inc (2020–2026)
Market capitalization of Oric Pharmaceuticals Inc from 2020 to today. Between 2020 and today, Oric Pharmaceuticals Inc's market cap moved from $3.51 Billion to $ 968.12 Million, with a yearly change of -14.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $968.12 Million | +14.18% |
| 2025 | $847.88 Million | +1.36% |
| 2024 | $836.48 Million | -12.28% |
| 2023 | $953.60 Million | +56.20% |
| 2022 | $610.51 Million | -59.93% |
| 2021 | $1.52 Billion | -56.57% |
| 2020 | $3.51 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Oric Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $968.12 Million USD |
| MoneyControl | $968.12 Million USD |
| MarketWatch | $968.12 Million USD |
| marketcap.company | $968.12 Million USD |
| Reuters | $968.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more